Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 3 pathways; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 14144
Sealed predictions
- CYB5R3 in dopamine neurons, braak+0.25 (p 0.517) → -0.80 (p 0.010)receipt 14150
Swarm cases
receipt 14150: CYB5R3 in dopamine neurons, braak
- power
- full sample -0.51 (p 0.032, n 18), 95% CI -0.79 to -0.05. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.49 (p 0.037, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.62 (p 0.0060, n 18). not the mix.
- skeptic
- leave-one-out range -0.62 to -0.44, sign flips 0; without severely affected donors -0.51 (p 0.032, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.70 (p 0.0012, n 18) vs -0.51 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CYB5R3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CYB5R3 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.47 p 0.091 (needs p < 1.6e-4)
Receipts
loading the receipts